Anti-melanoma differentiation-associated gene 5(MDA5)antibody-positive dermatomyositis is a subtype of DM characterized by a high propensity for developing interstitial lung disease,particularly rapidly progres-sive ILD(RPILD).Patients with RPILD often exhibit resistance to corticosteroid and immunosuppressive treatments,resulting in a high mortality rate of 70％despite active intervention,posing a serious threat to patient survival.There-fore,heightened attention to this condition is warranted.This article reviews the pathogenesis,clinical characteristics,and treatment advancements of anti-MDA5 positive dermatomyositis,with a particular emphasis on early identification and warning methods for RPILD in these patients.
DermatomyositisSigns and symptomsanti-MDA5Clinical protocols
维普
万方数据
